Market news

GAITHERSBURG, Md., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, Chief Executive Officer, Matthew Ferguson, Chief Financial Officer, and Dr. Michelle Williams, Chief Scientific Officer, will participate in two upcoming investor conferences. Lake Street Capital Markets 10th Annual Big Ideas Growth ConferenceElutia will host one-on-one meetings with investors at the

Detailed price information for Elutia Inc (ELUT-Q) from The Globe and Mail including charting and trades.

Detailed price information for Summit Therapeu ADR (SMMT-Q) from The Globe and Mail including charting and trades.

Elutia Completes SimpliDerm® Sale on Schedule, Adds $8 Million in Cash to Fund NXT-41x Through Full Commercial Launch...

Acquisition expands Cellution Biologics’ human tissue-based portfolio and marks its entry into the U.S. reconstructive surgery marketROSWELL, Ga., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Cellution Biologics Inc. (“Cellution Biologics” or the “Company”), a biologics company focused on developing, manufacturing and commercializing advanced human tissue-based products, today announced the completion of its acquisition of the SimpliDerm hydrated human acellular dermal matrix (ADM) business from Elutia Inc

Moby summary of Elutia Inc.'s Q2 2026 earnings call

$10 million funded at closing; second $5 million tranche unlocked upon FDA 510(k) clearance of NXT-41xPreserves shareholder value by funding commercialization of Elutia's next-generation antibiotic-eluting biomatrix without an equity offeringNXT-41x targets the 15–20% post-operative infection rates in multiple complex plastic and reconstructive surgical procedures GAITHERSBURG, Md., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-elutin

Independent Blinded Survey of 50 Plastic Surgeons Validates Demand; NXT-41 and NXT-41x Remain On-TrackFunded through launch: secured up to $26 million of capital without an equity offeringThe unmet need is real: 86% of surgeons surveyed say the matrices they use today increase infection riskThe demand is strong: 96% of surgeons surveyed are interested in adopting NXT-41x; 92% responded they would champion it at their hospital value analysis committeeOn track: NXT-41 FDA clearance decision expect

Elutia Inc (ELUT) reports Q2 2026 results, highlighting robust surgeon interest in NXT41X and a strengthened balance sheet despite a slight revenue dip.

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Detailed price information for Elutia Inc (ELUT-Q) from The Globe and Mail including charting and trades.

Detailed price information for Elutia Inc (ELUT-Q) from The Globe and Mail including charting and trades.

Elutia (NASDAQ:ELUT) sells SimpliDerm to Cellution Biologics for up to $11M to boost its balance sheet ahead of the NXT-41x launch.

Acquisition marks Cellution Biologics' entry into the U.S. reconstructive surgery market through an established human acellular dermal matrix platform.SimpliDerm® expands Cellution Biologics' advanced biologics portfolio beyond wound care, ocular repair, and other surgical applications into reconstructive surgery.Transaction supports Cellution Biologics' long-term strategy of building a global biologics platform while ensuring continuity of supply for existing customers. ROSWELL, Ga., July 16, 2

Transaction provides $8 million in cash at closing and up to $3 million in technology transfer and commercial milestone payments over the next 18 monthsProceeds provide additional non-dilutive capital to advance NXT-41x toward anticipated clearance and targeted commercial launch in 2027Divestiture sharpens Elutia’s focus on NXT-41x and the $1.5 billion plastic and reconstructive surgery opportunity GAITHERSBURG, Md., July 16, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “

Elutia (ELUT) said Thursday it entered into a definitive agreement to sell its SimpliDerm human acel